Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs.
Tumour cell heterogeneity is a major barrier for efficient design of targeted anti-cancer therapies. A diverse distribution of phenotypically distinct tumour-cell subpopulations prior to drug treatment predisposes to non-uniform responses, leading to the elimination of sensitive cancer cells whilst...
Main Authors: | Tomás Alarcón, Josep Sardanyés, Antoni Guillamon, Javier A Menendez |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-06-01
|
Series: | PLoS Computational Biology |
Online Access: | https://doi.org/10.1371/journal.pcbi.1008408 |
Similar Items
-
The role of multiple marks in epigenetic silencing and the emergence of a stable bivalent chromatin state.
by: Swagatam Mukhopadhyay, et al.
Published: (2013-01-01) -
Generation of bivalent chromatin domains during cell fate decisions
by: De Gobbi Marco, et al.
Published: (2011-06-01) -
In Silico Prediction of Therapeutic Drug Targets for Lung Cancer
by: Min-You Wu, et al.
Published: (2013) -
Noise-induced bistability in the fate of cancer phenotypic quasispecies: a bit-strings approach
by: Josep Sardanyés, et al.
Published: (2018-01-01) -
Changes of bivalent chromatin coincide with increased expression of developmental genes in cancer
by: Bernhart, Stephan H., et al.
Published: (2016)